(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 67.39%.
Cocrystal Pharma's earnings in 2026 is -$8,829,000.On average, 4 Wall Street analysts forecast COCP's earnings for 2026 to be -$9,422,345, with the lowest COCP earnings forecast at -$9,863,544, and the highest COCP earnings forecast at -$8,830,864. On average, 3 Wall Street analysts forecast COCP's earnings for 2027 to be -$9,000,449, with the lowest COCP earnings forecast at -$8,647,491, and the highest COCP earnings forecast at -$9,265,168.
In 2028, COCP is forecast to generate -$9,844,241 in earnings, with the lowest earnings forecast at -$9,458,193 and the highest earnings forecast at -$10,133,778.